Scholarlink

<p>Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of relapsed or refractory hematologic malignancies and continues to advance clinically. However, its broader application is hindered by heterogeneous efficacy, limited response durability, antigen-negative relapse, and both acute and delayed toxicities. Biomarkers are therefore critical for predicting clinical outcomes, optimizing product design, refining patient selection, evaluating early responses, and monitoring toxicities. In this review, we summarize current biomarkers across key biological compartments that determine CAR-T efficacy and safety: host-derived factors including baseline inflammatory profiles, immune composition, and T-cell fitness; product-related features such as CAR structure, cellular subsets, metabolic state, expansion, and persistence; tumor-derived markers including antigen expression, genomic characteristics, minimal residual disease, circulating tumor DNA, and tumor microenvironment. We also outline biomarkers associated with major CAR-T-related toxicities. Finally, we discuss how high-parameter flow cytometry, single-cell multi-omics, extracellular vesicles, and novel CAR platforms are advancing biomarker development. Collectively, these findings support a shift from individual candidate markers toward integrated longitudinal frameworks to guide precision CAR-T therapy and further improve efficacy, durability, and safety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biomarker-empowered precision navigation of CAR-T cell therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月23日

查看全文
  • Yuru Wang,
  • Weishi Cheng,
  • Kai Kang,
  • Ting Niu,
  • Ailin Zhao,
  • Yijun Wu

摘要

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of relapsed or refractory hematologic malignancies and continues to advance clinically. However, its broader application is hindered by heterogeneous efficacy, limited response durability, antigen-negative relapse, and both acute and delayed toxicities. Biomarkers are therefore critical for predicting clinical outcomes, optimizing product design, refining patient selection, evaluating early responses, and monitoring toxicities. In this review, we summarize current biomarkers across key biological compartments that determine CAR-T efficacy and safety: host-derived factors including baseline inflammatory profiles, immune composition, and T-cell fitness; product-related features such as CAR structure, cellular subsets, metabolic state, expansion, and persistence; tumor-derived markers including antigen expression, genomic characteristics, minimal residual disease, circulating tumor DNA, and tumor microenvironment. We also outline biomarkers associated with major CAR-T-related toxicities. Finally, we discuss how high-parameter flow cytometry, single-cell multi-omics, extracellular vesicles, and novel CAR platforms are advancing biomarker development. Collectively, these findings support a shift from individual candidate markers toward integrated longitudinal frameworks to guide precision CAR-T therapy and further improve efficacy, durability, and safety.